IS1-mediated DNA rearrangements.

H. Saedler,G. Cornelis,J. Cullum,B. Schumacher,H. Sommer

DOI: https://doi.org/10.1101/SQB.1981.045.01.017

Cold Spring Harbor Symposia on Quantitative Biology

Abstract:

What problem does this paper attempt to address?

Detection of male cells in mixtures containing varying proportions of male and female cells by fluorescence in situ hybridization and G-banding.

A. D. White,M. Sweeney

DOI: https://doi.org/10.1002/CYTO.990140104

Cytometry

Abstract:The efficiency and sensitivity of fluorescence in situ hybridization (FISH) and G-banding for the detection of male cells in mixtures of male and female cells derived from peripheral blood (PB) and bone marrow (BM) are compared. Zero false positive and negative rates were obtained with G-banding in all studies. False positive rates obtained with FISH were low (0-2.5%) in both PB and BM. False negative rates varied from 0-13.3%. Variations due to differences in fluorescent counterstain or scorers were not significant and in some cases the percentage of Y-positive cells as determined by FISH agreed more closely with the estimated frequency of male cells than that obtained by G-banding. The minimum limits of detection for FISH were 5% male cells on counting 500 PB or BM interphases; 10% male cells on counting 100 PB metaphases; and 20% male cells on counting 50 BM metaphases. This is in agreement with the theoretical limits of detection [95% confidence limit (CL)]. However, minimum levels of detection for female cells were below the 95% CL. It was not possible to reliably distinguish 95% female cells from 100% on counting 500 PB or BM interphases; 90% from 100% on counting 100 PB metaphases; or 80% from 100% on counting 50 BM metaphases.
Encephaloduroarteriosynangiosis Operative Technique and Intraoperative Anesthesia Management: Treatment From Both Sides of the Curtain

Miguel D. Quintero-Consuegra,N. Gonzalez,N. Martin,Z. Barnard,Daniel Chang,K. Ziv,B. Van de Wiele,J. Chan,R. Babadjouni

DOI: https://doi.org/10.1227/ONS.0000000000000009

IF: 2.817

2021-11-29

Operative Neurosurgery

Abstract:BACKGROUND: Encephaloduroarteriosynangiosis (EDAS) is a form of indirect revascularization for cerebral arterial steno-occlusive disorders. EDAS has gained growing interest as a technique applicable to pediatric and adult populations for several types of ischemic cerebral steno-occlusive conditions. OBJECTIVE: To present a team-oriented, multidisciplinary update of the EDAS technique for application in challenging adult cases of cerebrovascular stenosis/occlusion, successfully implemented in more than 200 cases. METHODS: We describe and demonstrate step-by-step a multidisciplinary-modified EDAS technique, adapted to maintain uninterrupted intensive medical management of patients' stroke risk factors and anesthesia protocols to maintain strict hemodynamic control. RESULTS: A total of 216 EDAS surgeries were performed in 164 adult patients, including 65 surgeries for patients with intracranial atherosclerotic disease and 151 operations in 99 patients with moyamoya disease. Five patients with intracranial atherosclerotic disease had recurrent strokes (3%), and there was one perioperative death. The mean clinical follow-up was 32.9 mo with a standard deviation of 31.1. There was one deviation from the surgical protocol. There were deviations from the anesthesia protocol in 3 patients (0.01%), which were promptly corrected and did not have any clinical impact on the patients' condition. CONCLUSION: The EDAS protocol described here implements a team-oriented, multidisciplinary adaptation of the EDAS technique. This adaptation resides mainly in 3 points: (1) uninterrupted administration of intensive medical management, (2) strict hemodynamic control during anesthesia, and (3) meticulous standardized surgical technique.

Medicine
Encephaloduroarteriosynangiosis for Symptomatic Intracranial Atherosclerotic Arterial Steno-Occlusive Disease: Clinical and Radiological Outcomes

Xiao-Peng Wang,Bin Ren,Qian-Nan Wang,Jing-Jie Li,Jia-Qi Liu,Dan Yu,Qian Zhang,Xiang-Yang Bao,Jian-Ning Zhang,Lian Duan

DOI: https://doi.org/10.1161/JAHA.124.034707

2024-08-06

Abstract:Background: This study investigated the long-term clinical and angiographic outcomes of encephaloduroarteriosynangiosis treatment for symptomatic intracranial atherosclerotic arterial steno-occlusive disease to further evaluate the potential therapeutic role of encephaloduroarteriosynangiosis in this population. Methods and results: A total of 152 adult patients with symptomatic intracranial atherosclerotic arterial steno-occlusive disease who were treated with encephaloduroarteriosynangiosis and intensive medical management across 3 tertiary centers in China between January 2011 and September 2019 were retrospectively included. The primary outcomes were defined as postoperative cerebrovascular events, including ischemic and hemorrhagic stroke. The postoperative neovascularization was analyzed qualitatively and quantitatively by using angiography. Clinical, radiological, and long-term follow-up data were analyzed using Cox regression, logistic regression, and linear regression analyses. Primary outcome rates were 3.2% (5/152) within 30 days, 6.6% (10/152) within 2 years, 9.2% (14/152) within 5 years, and 11.1% (17/152) during a median 9.13 years follow-up. Initial infarction symptoms were positively associated with recurrent ischemic stroke. Additionally, posterior circulation involvement and coexisting cardiac disease indicated poorer neurological status, whereas encephaloduroarteriosynangiosis neovascularization efficacy was negatively associated with older age and vascular risk factors but positively associated with posterior circulation involvement. Conclusions: Encephaloduroarteriosynangiosis plus intensive medical management appears efficacious and safe for symptomatic intracranial atherosclerotic arterial steno-occlusive disease, with low perioperative risk and favorable long-term results. Further prospective trials are needed to verify its efficacy and determine the optimal patient selection criteria.
Abstract TP202: Safety and Efficacy of Drug-Eluting Stents in Intracranial Atherosclerotic Disease: A Systematic Review and Meta-Analysis

Stefano Byer,Anand Dharia,Nihil Abraham,Kevin Le,Michael G Abraham

DOI: https://doi.org/10.1161/str.55.suppl_1.tp202

IF: 10.17

2024-02-01

Stroke

Abstract:Background: Advancements in arterial stenting technology have challenged prior notions favoring medical management over endovascular intervention for intracranial atherosclerotic disease (ICAD). Where previous conclusions were drawn from bare metal stent (BMS) technology, recent studies suggest drug-eluting stents (DES) are favorable over BMS due to their anti-proliferative effect. Methods: We conducted a systematic review and meta-analysis of the literature prior to August 2023 reviewing reports of ICAD treated with DES. Our target outcomes were incidence of any stroke, transient ischemic attack (TIA), or death within 30 days (post-procedural complications), ischemic stroke in the territory of the qualifying artery beyond 30 days (long-term complications), radiographically detected in-stent restenosis rate (ISR), and symptomatic ISR during follow-up. A subgroup analysis further stratified pre-procedural mean stenosis above and below 70% into severe and moderate cohorts, respectively. Results: PubMed and EMBASE query identified 518 candidate articles, from which 13 studies met inclusion criteria for a total of 475 patients and 508 ICAD lesions. Incidence of post-procedural complications was 8.1% (95% CI 3.1-15.1%) with subgroup analysis demonstrating significantly higher incidence in the severely stenotic group [10.4% (95% CI 5.7%-16.2%)] than the moderately stenotic group [3.0% (95% CI 0.7%- 6.8%)]. Long-term complications were 1.2% (95% CI 0.4%-2.4%). Radiographic ISR was 3.2% (95% CI 1.0%- 6.5%) and symptomatic ISR was 0.0% (95% CI 0.0%-0.5%). Conclusions: Our systematic review and meta-analysis suggest that DES can effectively reduce the risk of ISR and may be a viable treatment modality to reduce long-term complications in refractory ICAD patients.

peripheral vascular disease,clinical neurology
Long-term outcomes after conservative and EDAS treatment for 111 elderly patients with moyamoya disease: longitudinal and cross-sectional study

Jing-Jie Li,Xiao-Peng Wang,Qian-Nan Wang,Xiang-Yang Bao,Qing-Bao Guo,Zi-Qing Kong,Gan Gao,Min-Jie Wang,Si-Meng Liu,He-Guan Fu,Qian Zhang,Lian Duan

DOI: https://doi.org/10.3171/2023.7.jns231060

IF: 5.408

2023-09-01

Journal of Neurosurgery

Abstract:OBJECTIVE This study aimed to explore the clinical features of moyamoya disease (MMD) and the efficacy of encephaloduroarteriosynangiosis (EDAS) in elderly patients with MMD and to identify the risk factors for long-term stroke events. METHODS Clinical data were retrospectively collected on elderly patients with MMD (age ≥ 60 years) who had been treated at the authors’ center from May 2007 to December 2017. Clinical features, angiographic findings, and long-term outcomes (> 5-year follow-up) were analyzed. Cox regression analysis was performed to determine the risk factors for postoperative stroke events. Long-term stroke events were analyzed using Kaplan-Meier curves. RESULTS The mean age at symptom onset was 62.9 ± 3.0 years among 111 elderly patients with MMD. Vascular comorbidities were present in 80 (72.1%) patients. The ratio of female to male patients was 1:1.2. Familial MMD was found in 7 (6.3%) patients. Cerebral ischemia was the most common clinical manifestation observed in 82 (73.9%) patients. Most patients (59.5%) presented with Suzuki stages 5 and 6 MMD, and 29 (26.1%) patients presented with stenosis or occlusion of the posterior circulation. Unilateral MMD was present in 17 (15.3%) patients. Among the 58 (52.3%) patients who underwent EDAS, 28 (48.3%) and 30 (51.7%) underwent bilateral and unilateral surgeries, respectively. Overall, 53 (47.7%) patients were treated conservatively using internal medicine. After a median follow-up duration of 8.2 years, stroke incidence in the EDAS and conservative treatment groups was respectively 17.2% (7 and 3 cases of cerebral infarction and hemorrhage, respectively) and 49.1% (22 and 4 cases of cerebral infarction and hemorrhage, respectively). The stroke incidence rate was higher in the conservative group than in the EDAS group, with a statistically significant difference (p = 0.001) according to results of the Kaplan-Meier analysis. The identified predictor of postoperative stroke events was initial hemorrhage in the EDAS group and advanced age, aneurysm, and initial ischemia in the conservative treatment group. CONCLUSIONS The postoperative long-term stroke rate among elderly patients with MMD was lower in the EDAS group than in the conservative treatment group. Long-term stroke events were associated with advanced age, aneurysm, and initial ischemia after conservative treatment and only initial hemorrhage after EDAS.

surgery,clinical neurology
Borderzone infarction and recurrent stroke in intracranial atherosclerosis

Alexandra Kvernland,Jose Torres,Eytan Raz,Erez Nossek,Adam de Havenon,Mulugeta Gebregziabher,Pooja Khatri,Shyam Prabhakaran,David S Liebeskind,Shadi Yaghi

DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106897

Abstract:Background: Intracranial stenosis (ICAS) is a common cause of stroke worldwide and patients with symptomatic ICAS exhibit a high rate of recurrence, particularly in the early period after the initial event. In this study, we aimed to study the association between borderzone infarct and recurrent ischemic stroke in patients hospitalized with symptomatic ICAS. Methods: This is a retrospective single center study that included patients hospitalized with acute ischemic stroke in the setting of intracranial stenosis (50% or more and an acute ischemic stroke in the territory supplied by the stenosed artery) over a 32-month period. We excluded patients who did not receive a brain MRI or did not have an infarct on brain imaging. The primary predictor is infarct pattern (any borderzone vs. no borderzone infarct) and the primary outcome was recurrent cerebrovascular events (RCVE) within 90 days. We used unadjusted, and age and sex adjusted logistic regression models to determine associations between infarct pattern and RCVE at 90-days. Results: Among 99 patients who met the inclusion criteria (4 tandem), the mean age was 70.1 ± 11.2 years and 41.4% were women; 43 had borderzone infarcts and 19 had RCVE. In adjusted binary logistic regression analysis, borderzone infarct was associated with increased risk of RCVE (adjusted OR 4.00 95% CI 1.33-11.99, p=0.013). The association between borderzone infarction and RCVE was not different among anterior circulation ICAD (adjusted HR 2.85 95% CI 0.64-12.76, p=0.172) vs. posterior circulation ICAD (adjusted HR 6.69 95% CI 1.06-42.11, p=0.043), p-value for interaction = 0.592. Conclusion: In real world post-SAMMPRIS medically treated patients with ICAD, the borderzone infarct pattern was associated with 90-day RCVE. Borderzone infarcts are likely a surrogate marker of impaired distal blood flow, highlighting the importance of targeting stroke mechanisms and developing alternative treatment strategies for high-risk cohorts.
Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: A systematic review and meta-analysis

Gengfan Ye,Xiaoliang Yin,Ximeng Yang,Junjie Wang,Peng Qi,Jun Lu,Lijun Wang,Daming Wang

DOI: https://doi.org/10.1016/j.jocn.2018.10.118

Abstract:Drug-eluting stent (DES) is a potential endovascular treatment for patients with symptomatic intracranial atherosclerotic disease (sICAD). However, evidence regarding the treatment of ICAD with DES is lacking. We systematically searched Pubmed, Embase, Cochrane database (before 2017-12-21) for literature reporting the application of DES in the treatment of sICAD. The main outcomes were as follows: the incidence of any stroke or death within 30 days (perioperative complications), ischemic stroke in the territory of the qualifying artery beyond 30 days (long-term complications), in-stent restenosis rate (ISR) and symptomatic ISR during follow-up. Those studies with mean stenosis rate greater than 70% and less than 70% were defined as severe and moderate stenosis group, respectively. The random effect model was used to pool the data. Of 518 articles, 13 studies were eligible and included in our analysis (N = 336 patients with 364 lesions). After the implantation of DES, perioperative complications (mortality = 0) occurred in 6.0% (95%CI 2.0%-11.9%), long-term complications occurred in 2.2% (95%CI 0.7%-4.5%), ISR rate was 4.1% (95%CI 1.6%-7.7%) and the symptomatic ISR rate was only 0.5% (95%CI 0-2.2%). In addition, subgroup analysis showed that the perioperative complication rate in severe stenosis group [10.6% (95%CI 6.5%-15.7%)] was significantly (p < 0.01) higher than that in moderate stenosis group [1.0% (95%CI 0.3%-3.5%)]. In summary, endovascular DES implantation is a relatively safe and effective method compared with stents or medical management group in SAMMPRIS and VISSIT trials. However, a higher preoperative stenosis rate may imply a higher risk of perioperative complications. Further studies are needed.
Design of the "EAST" strategy in patients with asymptomatic intracranial atherosclerotic stenosis

Xinyu Chen,Jiaqi Dai,Ping Nie,Ping Gu,Min Wang,Kezhong Zhang,Zhaolu Wang

DOI: https://doi.org/10.1016/j.clineuro.2024.108507

2024-08-15

Abstract:Introduction: Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide and confers a high risk of stroke recurrence, despite aggressive medical therapy. Asymptomatic ICAS (aICAS) is a frequent finding on neuroimaging, and it's an independent risk factor for future stroke. Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and effectively lower low-density lipoprotein cholesterol levels. We hypothesize that extra alirocumab in addition to statin therapy (EAST) could stabilize intracranial plaques in patients with aICAS. Methods and analysis: In this prospective, randomized, open-label, blinded end-point study, we will use high-resolution vessel-wall magnetic resonance imaging (HR-vwMRI) to evaluate the efficacy and safety of alirocumab in patients with asymptomatic ICAS. Eighty patients with aICAS (50 %-99 %) caused by unstable plaques will be assigned to the arm of alirocumab plus statin therapy, or the arm of statin therapy in a 1:1 ratio. Patients will undergo HR-vwMRI at recruitment and after 6 months. The primary outcome is changes in plaque features evaluated by HR-vwMRI after 6 months' treatment. This trial is being conducted at the first affiliated hospital of Nanjing medical university, China. Ethics and dissemination: The study has been approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. Written informed consents will be obtained from all participants. Study results will be published as peer-reviewed articles. Trial registration number: ClinicalTrials.gov, Identifier: NCT06080256.
Hemodynamic Markers in the Anterior Circulation as Predictors of Recurrent Stroke in Patients With Intracranial Stenosis

Ashley M Wabnitz,Colin P Derdeyn,David J Fiorella,Michael J Lynn,George A Cotsonis,David S Liebeskind,Michael F Waters,Helmi Lutsep,Elena López-Cancio,Tanya N Turan,Jean Montgomery,L Scott Janis,Bethany Lane,Marc I Chimowitz,SAMMPRIS Investigators

DOI: https://doi.org/10.1161/STROKEAHA.118.020840

IF: 10.17

Stroke

Abstract:Background and Purpose- Although aggressive medical therapy was superior to stenting in the SAMMPRIS trial (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis), the stroke rate in the medical arm was still high. The aim of this study was to determine the association between hemodynamic markers (borderzone infarct pattern and impaired collateral flow on baseline imaging) and rates of recurrent stroke in patients treated medically in SAMMPRIS. Methods- This was a post hoc analysis of patients whose qualifying event for SAMMPRIS was an infarct in the territory of a stenotic middle cerebral artery or intracranial carotid artery. Infarcts were adjudicated as involving primarily internal or cortical borderzone territories, the core middle cerebral artery territory, or perforator territories, and collateral flow was assessed according to a standard scale (American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology). Log-rank tests and χ2 tests were performed to assess associations of infarct patterns and collateral flow with rates of recurrent stroke. Results- Of 101 patients who qualified, 14 of 53 (26.4%) with borderzone infarcts, 2 of 24 (8.3%) with core middle cerebral artery infarcts, and 3 of 24 (12.5%) with perforator infarcts had a recurrent stroke in the territory (P=0.14 for comparing the 3 groups, P=0.052 for borderzone versus nonborderzone). Of 82 patients with collateral flow assessment, 30 of 43 (70%) with borderzone infarcts, 7 of 19 (37%) with core middle cerebral artery infarcts, and 11 of 20 (55%) with perforator infarcts had impaired collateral flow distal to the stenosis (P=0.049). Patients with borderzone infarcts and impaired collateral flow had the highest risk of recurrent stroke (37%). Conclusions- Borderzone infarcts and impaired collateral flow identify a subgroup of patients with intracranial stenosis who are at particularly high risk of recurrent stroke on medical treatment. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT00576693.
Effect of Drug-Coated Balloon Versus Stent Angioplasty in Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Bei Li,Qiang Bian,Heju Li,Yingkun He,Songtao Chen,Kun Zhang,Ziliang Wang

DOI: https://doi.org/10.1227/ons.0000000000001200

2024-05-23

Abstract:Background and objectives: Drug-coated balloons (DCBs) have exhibited promising results in coronary and peripheral artery diseases, but conclusive evidence is lacking in intracranial vasculature. We assessed the safety and efficacy of DCBs vs stent angioplasty for symptomatic intracranial atherosclerotic stenosis (sICAS) and initially identified patients who might have benefited most from DCB treatment. Methods: A single-center, retrospective cohort study was conducted from June 2021 to May 2022 with 154 patients with sICAS divided into 2 treatment groups: a DCB group (with or without remedial stenting, n = 47) and a stent group (n = 107). The treatment outcomes were compared using 1:2 propensity score matching. The primary safety end point was perioperative stroke or mortality, and the primary efficacy end point was the rate of target vessel restenosis at 12 months. The degree of luminal change was analyzed as a subgroup, defined as the difference between the degree of stenosis at follow-up and immediately after intervention. Results: One hundred eighteen patients were enrolled using propensity score matching, with 43 patients in the DCB group and 75 in the stent group. The incidence of perioperative adverse events was 2.3% in the DCB group and 8.0% in the stent group (P = .420). At a median follow-up of 12 months, the incidence of restenosis (11.9% [5/43] vs 28.0% [21/75], P = .045) and the median degree of stenosis (30% [20%, 44%] vs 30% [30%, 70%], P = .009, CI [0-0.01, 0.2]) were significantly lower in the DCB group than in the stent group. DCB angioplasty effectively prevented adverse events in the target vessel area and significantly reduced the degree of luminal change in the M1 segment of the middle cerebral artery (0 [0, 15%] vs 10% [0, 50%], P = .016). Conclusion: DCB angioplasty might be a safe and effective alternative to stent angioplasty to treat sICAS, particularly among patients with M1 segment of the middle cerebral artery stenosis.
Intracranial Atherosclerotic Disease in Acute Ischemic Stroke: Clinical Predictors, Imaging Profiles, and Treatment

Fawaz Alotaibi,Michael Mlynash,Muteb M. Aldawsari,Nowar Z. AlAbidien,Mohammed Alqahtani,Hussain Bin Amir,Ammar Alkawi,Abdulrahman Alreshaid,Mohamed AlZawahmah,Adel AlHazzani,Hani Alabdaly,Abdulmajeed Alanazi,Nouf Almansour,Gregory W Albers,Ashfaq Shuaib,Fahad S. AlAjlan

DOI: https://doi.org/10.1101/2024.11.24.24317863

2024-11-26

Abstract:Background: Intracranial atherosclerotic disease (ICAD) is a leading cause of ischemic stroke worldwide, with a significant prevalence in specific populations. This study aims to compare the clinical characteristics, imaging profiles, and outcomes of stroke patients with large vessel occlusion (LVO) caused by ICAD versus non-ICAD etiologies, particularly in those transferred for endovascular treatment (EVT). Methods: A retrospective analysis was conducted using data from the Riyadh Thrombectomy Registry, including 219 patients with acute ischemic stroke who underwent EVT between January 2019 and March 2024. Clinical, demographic, and imaging data were collected and compared between ICAD and non-ICAD groups. Imaging modalities included computed tomography perfusion (CTP) and angiography, with key metrics such as the hypoperfusion intensity ratio (HIR) and cerebral blood volume (CBV) index evaluated for prognostic utility. Results: Patients with ICAD were older and demonstrated a higher prevalence of vascular risk factors. ICAD patients presented with better ASPECTS scores, smaller ischemic core volumes, and higher mismatch ratios, reflecting better collateral circulation. However, despite favorable imaging profiles, ICAD patients exhibited higher mortality rates, particularly in cases involving basilar artery occlusion. HIR and CBV indices demonstrated modest diagnostic performance in distinguishing ICAD from non-ICAD, with an area under the curve (AUC) of 0.62 for HIR and 0.57 for CBV. Conclusions: ICAD patients undergoing EVT showed distinct clinical and imaging characteristics compared to non-ICAD patients. Despite better collateral circulation, ICAD is associated with higher mortality, especially in posterior circulation strokes. Further research is required to optimize EVT strategies and explore adjunctive therapies tailored to this challenging patient population.

Neurology
Safety and Efficacy of Direct Angioplasty in Acute Basilar Artery Occlusion Due to Atherosclerosis

Gaoting Ma,Xuan Sun,Xu Tong,Baixue Jia,Xiaochuan Huo,Gang Luo,Bo Wang,Yiming Deng,Feng Gao,Ligang Song,Ning Ma,Zhongrong Miao,Dapeng Mo

DOI: https://doi.org/10.3389/fneur.2021.651653

IF: 3.4

2021-07-19

Frontiers in Neurology

Abstract:Background and Purpose: Endovascular treatment (EVT) is one of the promising treatment options in patients with intracranial atherosclerotic disease (ICAD)-related basilar artery occlusion (BAO). In this study, we compared the safety and efficacy of direct angioplasty (DA) with stent-retriever thrombectomy (SRT) with or without rescue treatment in ICAD-related BAO. Methods: We retrospectively evaluated 187 patients who underwent EVT for BAO from January 2012 to July 2018. We identified patients who underwent EVT due to ICAD-related BAO. Patients who accepted SRT with or without rescue treatment were classified into the SRT group. Patients treated with DA with or without stent placement were classified into DA group. Clinical and laboratory findings and outcomes were compared between groups. Results: A total of 108 patients were enrolled, among them 77 underwent SRT and 31 underwent DA; 61 (79.2%) SRT group patients underwent angioplasty with or without stent placement. Compared with patients in the SRT group, those in the DA group experienced a significantly shorter procedure time [60 min (60–120 min) vs. 120 min (60–120 min); p = 0.038] and a lower number of device passes [2 passes (1–2 passes) vs. 3 passes (2–4 passes); p < 0.001]. No significant differences in balloon angioplasty (35.5 vs. 22.1%; p = 0.150), emergent stent placement (64.5 vs. 57.1%; p = 0.481), successful recanalization (93.5 vs. 85.7%; p = 0.340), embolization in distal or new territory (3.2 vs. 9.1%, p = 0.314), and reocclusion (22.6 vs. 9.1%; p = 0.109) among DA and SRT groups were found. Additionally, no differences in symptomatic intracranial hemorrhage incidence [adjusted odds ratio (OR), 0.74; 95% CI, 0.06–9.44; p = 0.815], functional independence (adjusted OR, 1.44; 95% CI, 0.50–4.16; p = 0.497), and mortality rate (adjusted OR, 0.36; 95% CI, 0.06–2.04; p = 0.247) were noted among groups. Conclusions: In certain patients with ICAD-related BAO, DA may shorten procedure time and reduce required device passes compared to SRT. In this study, DA was retrospectively found to be of similar safety and efficacy as SRT.

neurosciences,clinical neurology
Experimental Physiology - Symposium Report The ageing endothelium, cardiovascular risk and disease in man

D. Versari,E. Daghini,A. Virdis,L. Ghiadoni,S. Taddei

Abstract:Ageing is a major risk factor for cardiovascular disease, not only because there is a process of vascular ageing per se but also because ageing increases the time of exposure to other cardiovascular risk factors. Endothelial dysfunction is now considered an early and important mechanismthatpredisposestoatherothromboticdamageandthuscontributestotheoccurrence of cardiovascular events. The normal endothelium exerts a major vascular-protecting role by secreting substances, the most important of which is nitric oxide (NO). In disease conditions (such as the presence of cardiovascular risk factors), activation of endothelial cells can lead to the production and release of contracting factors, which counteract the beneficial effects of NO, and reactive oxygen species (ROS), which cause NO breakdown. Besides the opposite effects on vascular tone, NO and endothelium-derived contracting factors also respectively inhibit and activate several other mechanisms that are involved in the pathogenesis of atherothrombosis. Moreover, endothelial dysfunction is associated with vascular subclinical damage and, importantly, an increasing body of evidence strongly suggests that it might be an independent predictor for the risk of future cardiovascular events. Like the other traditional risk factors, ageing has been demonstrated to be associated with progressive impairment of endothelial function, in both conduit arteries and resistance vessels, mainly because of an increased production of ROS. Therefore, it is conceivable that endothelial dysfunction plays a major role in predisposing to age-related increased cardiovascular risk in the elderly.
Risk of Recurrence of Symptomatic Intracranial Atherosclerosis in Posterior Circulation Seen to Be Higher Than That in Anterior Circulation in Long-Term Follow-Up

Jingyu Zhang,Kai Zhang,Baixue Jia,Zhongqi Qi,Dapeng Mo,Ning Ma,Feng Gao,Zhongrong Miao

DOI: https://doi.org/10.3389/fneur.2020.574926

2020-11-06

Abstract:Background: Intracranial atherosclerotic stenosis (ICAS) is an important cause of ischemic stroke. In Asians, intracranial atherosclerotic disease leads to 33-50% of ischemic events. At present, treatment with medication vs. endovascular therapy (EVT) for symptomatic ICAS (sICAS) patients is still debatable. The clinical prognosis of patients who are not completely free of stroke symptoms despite regular medication and are not eligible for EVT for various reasons, is not yet investigated. Aim: To report the long-term recurrence rate of stroke in a cohort of symptomatic ICAS patients who intended to undergo EVT upon admission but could not for various reasons after digital subtraction angiography (DSA) evaluation. Method: This is a retrospective analysis of consecutive sICAS patients in a single center from January 1, 2016 to August 31, 2017 who underwent DSA assessment alone and were not eligible for further EVT. Demographic information, risk factors related to cerebrovascular disease, clinical comorbidities, medication, imaging data, and long-term outcomes were reported. Results: A total of 218 patients were included in the study; 42 (19.2%) patients had recurrence of stroke/transient ischemic attack (TIA) at the 1-year follow up. Patients were divided into two groups according to lesions in anterior circulation (n = 120) or posterior circulation (n = 98). There was a higher stroke/TIA recurrence rate in the posterior circulation than anterior circulation group (25.5 vs. 14.2%, p = 0.035). Given the advanced age, higher prevalence of coronary heart disease, larger stenosis length, and poorer collateral circulation, the posterior circulation group showed a higher risk of recurrent stroke/TIA and death than the anterior circulation group [HR = 3.092, 95% CI (1.335-7.164), p = 0.0084], after adjusting for all confounding factors in the COX regression model. Kaplan-Meier analysis showed that sICAS recurrence and mortality risk in the posterior circulation group was consistently higher than that in the anterior circulation group (log-rank-test, p = 0.033). Conclusions: Patients with posterior circulation sICAS have higher recurrence risk than those with anterior circulation managed with medication alone. Further, posterior circulation lesion is an independent risk factor for recurrence in sICAS patients.
Intracranial dolichoectasia in patients with symptomatic intracranial atherosclerotic disease: Results from the MYRIAD study

Victor J Del Brutto,Shyam Prabhakaran,David S Liebeskind,Iszet Campo-Bustillo,George Cotsonis,Azhar Nizam,Jose G Romano,of the MYRIAD Investigators

DOI: https://doi.org/10.1111/jon.12872

Abstract:Background and purpose: It is unknown whether intracranial atherosclerotic disease (ICAD), in addition to causing stenosis, also associates with abnormal arterial enlargement, a condition known as intracranial dolichoectasia (IDE). Across symptomatic ICAD patients, we aim to determine IDE prevalence and IDE impact on cerebral hemodynamics and recurrent cerebral ischemia. Methods: We analyzed 98 participants (mean age 63.8 ± 11.9 years, 56.1% men) of the prospective observational study MYRIAD. Participants were enrolled within 21 days of an ischemic stroke or transient ischemic attack caused by moderate-to-severe ICAD. Semi-automatic vessel segmentation was used to determine diameters, length, and tortuosity-index of proximal intracranial arteries. Either ectasia (increased diameter) or dolichosis (increased length or TI) defined IDE. We assessed IDE association with new infarcts during 12-month follow-up, and IDE correlation with cerebral hemodynamics determined by quantitative MR-angiography (QMRA), MR-perfusion weighted-imaging, and transcranial Doppler breath-holding index. Results: IDE was present in 35.7% of patients and 10.2% of symptomatic arteries. Basilar stenosis was associated with higher IDE prevalence (27.8% vs. 8.8%, p = 0.04), whereas other symptomatic arteries showed no association with IDE. Symptomatic arteries with IDE had lower hypoperfusion prevalence on MR-PWI (11.1% vs. 28.4%, p = 0.03). Increased diameter (r = 0.33, p<0.01) and tortuosity-index (r = 0.29, p = 0.01) showed positive correlation with QMRA flow rate. IDE was not associated with new infarcts during follow-up. Conclusions: IDE was common among symptomatic ICAD patients. IDE was not associated with stroke recurrence. Instead, increased diameter and tortuosity correlated with improved blood flow across the stenotic artery, suggesting that IDE may originate as an adaptive mechanism in ICAD.
European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease

Marios Psychogios,Alex Brehm,Elena López-Cancio,Gian Marco De Marchis,Elena Meseguer,Aristeidis H Katsanos,Christine Kremer,Peter Sporns,Marialuisa Zedde,Adam Kobayashi,Jildaz Caroff,Daniel Bos,Sabrina Lémeret,Avtar Lal,Juan F Arenillas

DOI: https://doi.org/10.1177/23969873221099715

IF: 6.1

2022-06-05

European Stroke Journal

Abstract:European Stroke Journal, Ahead of Print. The aim of the present European Stroke Organisation guideline is to provide clinically useful evidence-based recommendations on the management of patients with intracranial atherosclerotic disease (ICAD). The guidelines were prepared following the Standard Operational Procedure of the European Stroke Organisation guidelines and according to GRADE methodology. ICAD represents a major cause of ischemic stroke worldwide, and patients affected by this condition are exposed to a high risk for future strokes and other major cardiovascular events, despite best medical therapy available. We identified 11 relevant clinical problems affecting ICAD patients and formulated the corresponding Population Intervention Comparator Outcomes (PICO) questions. The first two questions refer to the asymptomatic stage of the disease, which is being increasingly detected thanks to the routine use of noninvasive vascular imaging. We were not able to provide evidence-based recommendations regarding the optimal detection strategy and management of asymptomatic ICAD, and further research in the field is encouraged as subclinical ICAD may represent a big opportunity to improve primary stroke prevention. The second block of PICOs (3–5) is dedicated to the management of acute large vessel occlusion (LVO) ischemic stroke caused by ICAD, a clinical presentation of this disease that is becoming increasingly relevant and problematic, since it is associated with more refractory endovascular reperfusion procedures. An operational definition of probable ICAD-related LVO is proposed in the guideline. Despite the challenging context, no dedicated randomized clinical trials (RCTs) were identified, and therefore the guideline can only provide with suggestions derived from observational studies and our expert consensus, such as the escalated use of glycoprotein IIb-IIIa inhibitors and angioplasty/stenting in cases of refractory thrombectomies due to underlying ICAD. The last block of PICOs is devoted to the secondary prevention of patients with symptomatic ICAD. Moderate-level evidence was found to recommend against the use of oral anticoagulation as preferred antithrombotic drug, in favor of antiplatelets. Low-level evidence based our recommendation in favor of double antiplatelet as the antithrombotic treatment of choice in symptomatic ICAD patients, which we suggest to maintain during 90 days as per our expert consensus. Endovascular therapy with intracranial angioplasty and or stenting is not recommended as a treatment of first choice in high-grade symptomatic ICAD (moderate-level evidence). Regarding neurosurgical interventions, the available evidence does not support their use as front line therapies in patients with high-grade ICAD. There is not enough evidence as to provide any specific recommendation regarding the use of remote ischemic conditioning in ICAD patients, and further RCTs are needed to shed light on the utility of this promising therapy. Finally, we dedicate the last PICO to the importance of aggressive vascular risk factor management in ICAD, although the evidence derived from RCTs specifically addressing this question is still scarce.
Abstract WP183: Intracranial Atherosclerotic Disease in Acute Basilar Artery Occlusion

Adam T Mierzwa,Sami Al Kasab,Ashley Nelson,Santiago Ortega,Juan Vivanco-Suarez,Mudassir Farooqui,Ashutosh P Jadhav,Shashvat Desai,Gabor Toth,Anas Alrohimi,Thanh Nguyen,Piers Klein,Mohamad AbdalKader,Aditya Pandey,Sravanthi Koduri,Shivangi Vora,Nameer Aladamat,Khaled Gharaibeh,Ehad Afreen,Syed Zaidi,Mouhammad A Jumaa

DOI: https://doi.org/10.1161/str.55.suppl_1.wp183

IF: 10.17

2024-02-01

Stroke

Abstract:Background: Intracranial Atherosclerotic Disease (ICAD) large vessel occlusion (LVO) is responsible for up to 30% of anterior circulation LVOs and is less amenable to mechanical thrombectomy. In this study we aim to determine the prevalence of ICAD acute basilar occlusion and the likelihood of favorable functional outcomes (mRS 0-3) compared to embolic basilar occlusion. Methods: This is an analysis of PC-SEARCH Thrombectomy Registry in which consecutive patients with acute basilar artery occlusions from 8 high-volume comprehensive stroke centers were included from January 2015 to December 2021. Patients were dichotomized into two cohorts: with or without underlying ICAD. Descriptive statistics for each group and multivariate logistic analysis was performed on the primary outcome. Results: Three-hundred-ninety-nine patients were included in this analysis. There were 143 (36%) and 256 (64%) patients with and without ICAD; respectively. Baseline demographics were equivalent between the two groups except for gender (male 67% vs 47%; p < 0.001), history of stroke (24% vs 14%; p = 0.01), and atrial fibrillation (18% vs 30%; p = 0.01). Presenting NIHSS was similar between groups (15 vs 16; p = 0.85), however, pc-ASPECTS was higher in the ICAD group (9 vs 8; p = 0.02). At 90 days, patients with ICAD were less likely to achieve favorable functional outcomes (OR 0.33 95% CI 0.18 - 0.59; p < 0.001) after adjusting for potential confounding factors. Additionally, ICAD patients were less likely to achieve TICI ≥2b (38% vs 49%; p < 0.001). There were equivalent rates of symptomatic ICH between groups (OR 0.8 95% CI 0.29 - 2.22; p = 0.66). Conclusion: Acute basilar artery occlusions with underlying ICAD have higher likelihood of morbidity and mortality. Lower rates of successful recanalization in the ICAD cohort support this finding; however, rates of sICH were similar between the two cohorts.

peripheral vascular disease,clinical neurology
High-Risk Intracranial Atherosclerotic Stenosis Despite Aggressive Medical Treatment: Protocol for a Prospective Nested Case-Control Study

Tao Wang,Jichang Luo,Changyi Liu,Bin Yang,Ran Xu,Long Li,Kun Yang,Chao Zhang,Yabing Wang,Yanfei Chen,Peng Gao,Jian Chen,Liqun Jiao,Yan Ma

DOI: https://doi.org/10.3389/fneur.2022.803224

IF: 3.4

2022-04-14

Frontiers in Neurology

Abstract:Introduction: Intracranial atherosclerotic disease (ICAD) is one of the most important etiologies of ischemic stroke, especially in Asia. Although medical treatment was recommended as the first-line therapy for ICAD, the recurrent stroke rate was still high in severe stenosis of ICAD despite aggressive medical treatment. Traditionally, the degree of luminal stenosis is used as the principal index for stroke risk stratification in patients with ICAD, while recent evidence suggested that symptomatic atherosclerotic plaques were characterized by plaque features and hemodynamics. This prospective, longitudinal, and nested case-control study aims to identify multimodal imaging predictors of high-risk patients with ICAD refractory to medical treatment and explore a refined risk stratification model based on the above multimodal imaging predictors. Methods: This prospective, longitudinal, and nested case-control study includes 400 symptomatic patients with ICAD with 50–99% of stenosis treated with aggressive medical therapy. All patients who meet the eligibility criteria are assessed by multimodal imaging examination from three aspects, including lumen stenosis, plaque characteristics, and hemodynamic features. The enrolled patients receive aggressive medical management, including antiplatelet therapy and cardiovascular risk control. The primary outcome is ischemic stroke or death attributable to the lesion of the target vessel within 1 year. The secondary endpoints are (1) any stroke or death; (2) all-cause mortality; (3) any stroke out of the territory of the responsible lesion; (4) functional outcome with the modified Rankin Scale (mRS). Ethics and Dissemination: This study has been approved by the ethics committee of our center ([2021]083) and has been prospectively registered (Registration No: ChiCTR2100048832). Study findings will be disseminated through peer-reviewed publications and presentations at scientific meetings.

neurosciences,clinical neurology
Maintenance of anaesthesia in sheep with isoflurane, desflurane or sevoflurane

A. Mohamadnia,G. Hughes,K. Clarke

DOI: https://doi.org/10.1136/vr.163.7.210

2008-08-16

Abstract:Rapid recovery from anaesthesia is advantageous in small ruminants, to reduce the risk of regurgitation. Theoretically, the least soluble inhalation agents should result in the fastest recoveries, but using additional injectable agents may negate this advantage. This study compared three inhalation agents for the maintenance of anaesthesia in sheep. Eighteen ewes that were to undergo orthopaedic surgery were allocated to one of three groups. Each group was premedicated with xylazine (0·1 mg/kg intramuscularly), anaesthesia was induced using ketamine (2 mg/kg) and midazolam (0·03 mg/kg) intravenously and analgesia provided by buprenorphine (0·008 mg/kg intramuscularly). Anaesthesia was then maintained with either isoflurane, sevoflurane or desflurane. Cardiopulmonary parameters were monitored throughout. All three inhalation agents provided adequate stable anaesthesia and there was no significant difference between the groups in their cardiopulmonary parameters or their recovery times. The mead (sd) postanaesthetic times to first swallow, first chewing attempts and ability to maintain their head lifted for five minutes were, respectively, 3·95 (2·53), 6·37 (3·68) and 32·8 (18·1) minutes for isoflurane, 3·62 (0·98), 7·66 (0·78) and 38·8 (16·6) minutes for sevoflurane, and 4·37 (1·65), 6·95 (1·52) and 29·8 (11·5) minutes for desflurane. Two sheep had poor quality recoveries after the use of sevoflurane, but all the other sheep recovered uneventfully. All three inhalation agents were suitable for the maintenance of anaesthesia in sheep but, as used in this study, there were no differences between them in speed of recovery.
Neuroform EZ Stenting for Symptomatic Intracranial Artery Stenosis: 30 Days Outcomes in a High-Volume Stroke Center

Haowen Xu,Tao Quan,Osama O. Zaidat,Dapu Chen,Zibo Wang,Yongjie Yuan,Baojun Yan,Hong Lu,Sheng Guan

DOI: https://doi.org/10.3389/fneur.2019.00428

IF: 3.4

2019-05-16

Frontiers in Neurology

Abstract:Objective: To test whether Neuroform EZ stent placement combined with the modified techniques in symptomatic severe intracranial stenosis (ICAS) would result in lower rates of peri-procedural complications of intracranial stenting.Methods: We retrospectively reviewed the clinical data from 71 consecutive patients who underwent Neuroform EZ stent placement combined with the modified techniques for symptomatic severe ICAS at our institute between January 2016 and October 2017. The primary outcomes were ipsi-lateral ischemic stroke, intra-cerebral hemorrhage, or death within 30 days after stenting. The secondary outcome was technical success.Results: The technical success rate was 100%. The mean pre and post-stent stenoses were 84.2% ± 9.1% (median 85%, IQR75% to 90%) and 16.9% ± 10.2 % (median 15%, IQR 10% to 25%). The frequency of ipsi-lateral stroke, intra-cerebral hemorrhage, or death within 30 days was 0%.Conclusions: The combined use of Neuroform EZ stent placement and the modified techniques for symptomatic severe ICAS is technically feasible and safe, with very low peri-procedural complications. Further studies are required to assess the long-term results of this approach.

neurosciences,clinical neurology

IS1-mediated DNA rearrangements.

Detection of male cells in mixtures containing varying proportions of male and female cells by fluorescence in situ hybridization and G-banding.

Encephaloduroarteriosynangiosis Operative Technique and Intraoperative Anesthesia Management: Treatment From Both Sides of the Curtain

Encephaloduroarteriosynangiosis for Symptomatic Intracranial Atherosclerotic Arterial Steno-Occlusive Disease: Clinical and Radiological Outcomes

Abstract TP202: Safety and Efficacy of Drug-Eluting Stents in Intracranial Atherosclerotic Disease: A Systematic Review and Meta-Analysis

Long-term outcomes after conservative and EDAS treatment for 111 elderly patients with moyamoya disease: longitudinal and cross-sectional study

Borderzone infarction and recurrent stroke in intracranial atherosclerosis

Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: A systematic review and meta-analysis

Design of the "EAST" strategy in patients with asymptomatic intracranial atherosclerotic stenosis

Hemodynamic Markers in the Anterior Circulation as Predictors of Recurrent Stroke in Patients With Intracranial Stenosis

Effect of Drug-Coated Balloon Versus Stent Angioplasty in Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Intracranial Atherosclerotic Disease in Acute Ischemic Stroke: Clinical Predictors, Imaging Profiles, and Treatment

Safety and Efficacy of Direct Angioplasty in Acute Basilar Artery Occlusion Due to Atherosclerosis

Experimental Physiology - Symposium Report The ageing endothelium, cardiovascular risk and disease in man

Risk of Recurrence of Symptomatic Intracranial Atherosclerosis in Posterior Circulation Seen to Be Higher Than That in Anterior Circulation in Long-Term Follow-Up

Intracranial dolichoectasia in patients with symptomatic intracranial atherosclerotic disease: Results from the MYRIAD study

European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease

Abstract WP183: Intracranial Atherosclerotic Disease in Acute Basilar Artery Occlusion

High-Risk Intracranial Atherosclerotic Stenosis Despite Aggressive Medical Treatment: Protocol for a Prospective Nested Case-Control Study

Maintenance of anaesthesia in sheep with isoflurane, desflurane or sevoflurane

Neuroform EZ Stenting for Symptomatic Intracranial Artery Stenosis: 30 Days Outcomes in a High-Volume Stroke Center